Beam Therapeutics Says FDA Lifts Clinical Hold on IND Application for BEAM-201

By Chris Wack

Beam Therapeutics Inc. said Friday that the U.S. Food and Drug Administration has lifted the clinical hold and cleared the Investigational New Drug application for BEAM-201 for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma.

The biotechnology company said its BEAM-201 is a specific anti-CD7, multiplex-edited, allogeneic chimeric antigen receptor T-cell development candidate.

"The FDA's clearance of our IND for BEAM-201 is an exciting moment for Beam and for the field of gene editing, as it represents the first IND clearance for a multiplex-base edited investigational drug," said John Evans, chief executive of Beam.

Beam shares were up 11% to $51 in premarket trading.

Write to Chris Wack at [e-mail]

(END) Dow Jones Newswires

12-02-22 0655ET